Cargando...
Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
OBJECTIVE: To determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active ankylosing spondylitis (AS) who have not responded adequately to previous treatment with conventional care (CC; biologic-naïve population) or previous biologic the...
Gardado en:
| Publicado en: | Pharmacoeconomics |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer International Publishing
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6021464/ https://ncbi.nlm.nih.gov/pubmed/29797186 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-018-0675-9 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|